Genetic Developmental and Epileptic Encephalopathy (DEE) — Comprehensive Research Report

1. Disease Information

Overview. Developmental and Epileptic Encephalopathy (DEE) is a diagnostic category — not a single disease — formalized by the ILAE 2017 Classification and refined by the ILAE Task Force on Nosology and Definitions in 2022, which split early-onset epilepsy syndromes into (a) self-limited epilepsies with age-related spontaneous remission and (b) DEEs, in which seizures and/or the underlying epileptiform activity itself contribute to a progressive or static encephalopathy with developmental impairment that is independent of (and often precedes) seizure onset. "Genetic DEE" denotes the subset — now understood to be the majority of DEE cases once modern sequencing is applied — in which a single-gene (monogenic) or, less commonly, oligogenic/copy-number variant is the etiology, as opposed to structural (malformations, HIE, stroke), metabolic, infectious, or immune causes. DEEs are the most severe end of the developmental and epileptic spectrum: drug-resistant seizures of multiple types, epileptiform EEG abnormalities, and intellectual disability/developmental regression, typically presenting in infancy or early childhood. (MedLink Neurology; Nature Reviews Disease Primers 2024, Scheffer et al., DOI:10.1038/s41572-024-00546-6; Epilepsy Foundation)

Key identifiers. - OMIM Phenotypic Series: PS308350 — "Developmental and epileptic encephalopathy," an umbrella series currently listing 123 numbered entries (DEE1 through DEE9x+), each corresponding to a distinct causal gene (e.g., DEE1/ARX #308350, DEE2/CDKL5 #300672, DEE9/PCDH19 #300088, DEE42/GRIN1 #617106, DEE50/CACNA1A #616457). - MONDO: the umbrella concept maps to MONDO:0010246 ("developmental and epileptic encephalopathy," a grouping term cross-referencing OMIM PS308350); individual gene-defined subtypes each carry their own MONDO ID (e.g., DEE2/CDKL5 disorder, DEE9/PCDH19-clustering epilepsy). - Orphanet: listed both as an umbrella grouping and as ~100+ individual gene-specific ORPHA entries (e.g., Dravet syndrome ORPHA:33069, CDKL5 deficiency disorder, STXBP1 encephalopathy). - ICD-11: most individual DEEs fall under 8A61-8A62 (developmental and epileptic encephalopathy codes) in the ICD-11 neurology chapter, replacing the non-specific ICD-10 G40.x/Q04 mappings. - MeSH: "Epileptic Syndromes," "Spasms, Infantile" and related descriptors are used as approximations; there is no single dedicated MeSH heading for genetic DEE as a class.

Synonyms/alternative names: "genetic epileptic encephalopathy," "early-onset epileptic encephalopathy (EOEE)," "malignant epilepsy of infancy," historically overlapping with "West syndrome," "Ohtahara syndrome," "early myoclonic encephalopathy (EME)," "Dravet syndrome," "Lennox-Gastaut syndrome," and (per the current 2022 ILAE nosology) many are now renamed with the causal gene as the syndrome name (e.g., "SCN1A-DEE," "STXBP1-DEE," "KCNQ2-DEE"). The 2022 ILAE terminology also folds in "developmental encephalopathy" (developmental impairment without frequent epileptiform activity) and "epileptic encephalopathy" (impairment driven mainly by epileptiform activity) as component concepts within the DEE spectrum.

Data provenance: Most of the literature base is aggregated disease-level knowledge (case series, gene-specific natural history cohorts, systematic reviews, ClinVar/gene-disease curation, and increasingly large national/international patient registries such as the RIKEE, Rare Epilepsy Network, and gene-specific foundation registries — e.g., FamilieSCN2A, CDKL5 Centers of Excellence). A growing minority is derived from population-based, prospective individual-level EHR/clinical cohorts (e.g., the Scottish national cohort, PMID:31363746, and the companion "Epidemiology of DEE" study, PMID:36581463) that ascertain every child with new-onset seizures in a defined region/time window — these are the most reliable source of incidence/prevalence figures cited below.

2. Etiology

Disease causal factors. By definition, genetic DEE is caused by a pathogenic variant — usually a de novo, heterozygous, single-nucleotide or small indel variant — in one of a rapidly growing list of genes. Next-generation sequencing (whole-exome/whole-genome sequencing, WES/WGS) has now implicated more than 900 genes in DEE pathogenesis. In clinical diagnostic cohorts, exome/panel sequencing establishes a molecular diagnosis in roughly 35–43% of unselected DEE cases (higher — ~41% — when seizure onset is under 2 years of age, vs. ~18% for later onset), reflecting how heavily the genetic architecture is skewed toward infantile-onset disease. (PubMed 35701389; PMC10816140; PMC12562696)

The most frequently implicated genes across diagnostic cohorts are SCN1A (Dravet syndrome — the single most common monogenic DEE, expected population frequency ≥1:20,000, and the archetype gene), STXBP1, SCN2A, KCNQ2, CDKL5, SCN8A, PCDH19 (X-linked, affects heterozygous females), GRIN1/GRIN2A/GRIN2B/GRIN2D, GABRA1/GABRB2/GABRB3/GABRG2, GNAO1, ARX, FOXG1, SPTAN1, and dozens of others (e.g., HCN1, FGF12, PLCB1, WWOX, SLC35A2, ST3GAL3, ATP6V1A). (EAN Spring School slide deck, McTague/Nabbout; PMC12562696)

Genetic risk factors. - Causal variants: predominantly de novo dominant (autosomal or X-linked). Recurrent "hotspot" pathogenic variants occur in several genes (e.g., KCNQ2 recurrent missense variants clustering in the pore/voltage-sensor domains). - Susceptibility/modifier loci are an active area of study but poorly characterized for most single-gene DEEs; polygenic background may modulate expressivity/severity in some genes (e.g., SCN1A modifier loci affecting Dravet syndrome severity, studied in mouse genetic background experiments). - Rare biallelic (autosomal recessive) forms exist for a subset of genes (e.g., some STXBP1, PIGA, and metabolic-DEE genes), and germline/somatic mosaicism is documented (notably for PCDH19, where affected females are typically heterozygous post-zygotic mosaic-unaffected-carrier males transmit to daughters — the "cellular interference" model).

Environmental risk factors: Largely not causal for genetic DEE per se, but febrile illness is a well-documented trigger/exacerbating factor in several gene-specific DEEs (e.g., fever-triggered seizure clusters in PCDH19-clustering epilepsy and in Dravet syndrome/SCN1A). Perinatal factors (prematurity, hypoxic injury) are relevant to the non-genetic DEE differential but are not causal for the monogenic forms; they may occasionally act as second hits modulating phenotype severity.

Protective factors: No established genetic protective variants for DEE broadly. In SCN1A-Dravet syndrome, some evidence suggests that variants reducing background Nav1.6 (SCN8A) function can partially compensate for Nav1.1 haploinsufficiency in mouse models (a genetic modifier concept), but this is not yet clinically actionable. Early, aggressive control of seizure burden and avoidance of sodium-channel-blocking antiseizure medications (contraindicated in SCN1A loss-of-function Dravet syndrome) function as protective clinical-management factors rather than biological protective factors.

Gene-environment interactions: The clearest documented interaction is fever/hyperthermia acting on genetically hyperexcitable or dysfunctional interneuron circuits (SCN1A, PCDH19) to precipitate seizure clusters — a mechanism actively studied with animal thermal-induction models.

3. Phenotypes

DEE phenotypes span symptoms/signs, laboratory/EEG abnormalities, and behavioral/cognitive manifestations. Representative phenotype categories with suggested HPO terms:

Characteristics. - Onset: highly gene-dependent — neonatal (KCNQ2, STXBP1, SCN2A/SCN8A gain-of-function, GNAO1), early infantile (SCN1A/Dravet ~5–8 months, CDKL5 <4 months, PCDH19 6–36 months), or later childhood in milder allelic series. - Severity/progression: typically progressive early, often plateauing; a subset (notably some KCNQ2-DEE) shows eventual seizure freedom (~73%) despite persistent severe intellectual disability — illustrating that seizure control and developmental outcome are partially dissociable, a key DEE concept. - Course: episodic seizure clustering is characteristic of PCDH19 and Dravet syndrome (fever-triggered clusters); other genes show a more chronic, drug-resistant daily-seizure pattern (e.g., CDKL5, STXBP1). - QoL impact: severe — most children require lifelong caregiver support; validated DEE-specific QoL instruments (e.g., the Quality of Life in Childhood Epilepsy [QOLCE], and newer DEE-specific PRO measures used in Dravet/CDKL5/STXBP1 trials) consistently show impairment across physical, cognitive, and family-burden domains. (Nature Reviews Disease Primers 2024 covers QoL explicitly per its abstract scope.)

4. Genetic/Molecular Information

Causal genes (representative, non-exhaustive; each an OMIM DEE phenotypic-series entry): - SCN1A (OMIM 182389; DEE6/Dravet syndrome #607208) — voltage-gated Na⁺ channel Nav1.1, predominantly expressed in GABAergic interneurons; loss-of-function (haploinsufficiency). - STXBP1 (602926; DEE4 #612164) — syntaxin-binding protein 1 (Munc18-1), core SNARE-complex regulator of synaptic vesicle fusion; predominantly loss-of-function/haploinsufficiency. - SCN2A (182390; DEE11 #613721) — Nav1.2, predominantly in excitatory neurons; both gain-of-function (early-infantile, severe) and loss-of-function (later-onset, milder, autism-predominant) variants cause distinct phenotypes on the same gene. - KCNQ2 (602235; DEE7 #613720) — Kv7.2 voltage-gated K⁺ channel subunit (M-current); dominant-negative or loss-of-function variants. - CDKL5 (300203; DEE2 #300672) — X-linked cyclin-dependent-kinase-like 5, a serine/threonine kinase important for neuronal synaptic maturation; loss-of-function. - SCN8A (600702; DEE13 #614558) — Nav1.6; typically gain-of-function. - PCDH19 (300460; DEE9 #300088) — X-linked protocadherin-19, a cell-adhesion molecule; unusually, affects heterozygous females (cellular-interference mechanism), while hemizygous males are typically unaffected carriers. - GRIN1/GRIN2A/GRIN2B/GRIN2D — NMDA receptor subunits; gain- or loss-of-function depending on variant location (pre-M1, M3, M4 helices). - GABRA1/GABRB2/GABRB3/GABRG2 — GABA-A receptor subunits; loss-of-function impairing GABAergic inhibition. - GNAO1 (139311; DEE17 #615473) — Gαo subunit; loss of cAMP-inhibitory function, also causes a prominent movement-disorder phenotype. - ARX (*300382; DEE1 #308350) — X-linked homeobox transcription factor; spectrum from lissencephaly to infantile spasms to isolated intellectual disability depending on variant type/location.

Pathogenic variant classification (ACMG/AMP via ClinVar/ClinGen): the overwhelming majority of reported DEE variants are classified Pathogenic/Likely Pathogenic; VUS remain common in less well-studied genes and require functional/segregation follow-up. Variant types: missense (most common, especially in channel/receptor genes — often clustering in functionally critical domains: pore, voltage-sensor, ligand-binding), frameshift/nonsense/splice-site (common in haploinsufficiency genes like STXBP1, CDKL5), and occasionally structural (partial gene deletions, e.g., in SLC35A2, or larger CNVs overlapping DEE loci).

Allele frequency: essentially absent from population databases (gnomAD, TOPMed) for the pathogenic DEE variants themselves, consistent with strong negative selection against de novo dominant, early-lethal/severely-disabling alleles — absence from gnomAD is itself used as supporting evidence (ACMG PM2) in variant classification.

Somatic vs. germline: the great majority of DEE-causing variants are germline de novo; parental germline mosaicism is well documented (important for recurrence-risk counseling, since apparently "de novo" variants can recur in siblings at rates of a few percent) and somatic mosaicism in the proband is documented for several genes (notably PCDH19 males, and mosaic SCN1A/SCN2A).

Functional consequences: span loss-of-function (channel/receptor haploinsufficiency, most common mechanism overall), gain-of-function (increased channel current, e.g., SCN2A/SCN8A early-infantile variants), and dominant-negative effects (e.g., some KCNQ2 pore variants disrupting tetrameric channel assembly) — the distinction is clinically critical because it determines precision-therapy direction (sodium-channel blockers help gain-of-function SCN2A/SCN8A but are contraindicated/harmful in loss-of-function SCN1A-Dravet syndrome).

Modifier genes: poorly characterized in humans; mouse genetic-background studies (e.g., Scn1a Dravet models on different inbred strains) show strong modifier effects on seizure severity and SUDEP risk, implicating candidate modifier loci not yet translated to human genetic counseling.

Epigenetic information: limited disease-specific data; FOXG1 and CDKL5 intersect with chromatin/transcriptional regulation pathways relevant to Rett-spectrum overlap. DNA methylation studies in DEE are largely investigational.

Chromosomal abnormalities: copy-number variants overlapping DEE genes (e.g., 15q11-q13 duplications affecting GABRB3, Xp22 deletions affecting CDKL5/ARX region) are recognized causes; array-based/ES-based CNV calling is now integrated into standard DEE diagnostic workups.

5. Environmental Information

Genetic DEE is, by definition, gene-driven, but several environmental modulators are clinically important: - Febrile illness/hyperthermia: the dominant seizure trigger in SCN1A-Dravet syndrome and PCDH19-clustering epilepsy; vaccination-associated fever can also trigger the first Dravet syndrome seizure (a well-documented but non-causal temporal association — vaccination does not cause the underlying SCN1A mutation). - Sleep deprivation, illness, and metabolic stress are general seizure-threshold-lowering factors across most DEEs, as in epilepsy generally. - Infectious agents: not a direct cause of genetic DEE, but concurrent/triggering infections (viral URIs, gastroenteritis) frequently precede seizure clusters. - Lifestyle/behavioral factors: not established as disease-modifying for genetic DEE specifically (contrast with acquired/structural epilepsies where perinatal/lifestyle factors are more directly causal).

6. Mechanism / Pathophysiology

The pathophysiology of genetic DEE converges on disrupted neuronal excitability and/or disrupted neurodevelopmental programs, broadly falling into two overlapping mechanistic classes reviewed in Nature Reviews Disease Primers 2024 (Scheffer et al.) and PMC11763800 "Pathogenesis of Intellectual Disability Beyond Channelopathies":

1. Channelopathies — direct disruption of voltage-gated ion channels (Na⁺: SCN1A/SCN2A/SCN8A/SCN1B; K⁺: KCNQ2/KCNQ3, KCNB1; Ca²⁺: CACNA1A) or ligand-gated channels (GABA-A receptor subunits, NMDA receptor subunits GRIN1/2A/2B/2D) causing an excitation/inhibition (E/I) imbalance. Mechanistically:
2. SCN1A loss-of-function selectively impairs Nav1.1 current in GABAergic interneurons (parvalbumin- and somatostatin-positive), producing disinhibition and network hyperexcitability — the accepted mechanism for Dravet syndrome.
3. SCN2A/SCN8A gain-of-function increases persistent/late Na⁺ current in excitatory pyramidal neurons, directly increasing intrinsic excitability; loss-of-function SCN2A variants instead impair excitatory neurotransmission and correlate with a milder, later-onset, autism-predominant phenotype — illustrating a single gene producing opposite mechanistic and clinical poles.
4. GABA-A receptor subunit variants (GABRA1/B2/B3/G2) directly reduce phasic and/or tonic inhibitory GABAergic signaling; tonic (extrasynaptic GABA-A-receptor-mediated) inhibition disruption is an emerging, specifically implicated DEE mechanism.

5. GRIN2B and related NMDA receptor variants (pre-M1/M3/M4 helix) alter glutamatergic excitatory drive and can be gain- or loss-of-function depending on variant location.

6. Synaptopathies / neurodevelopmental-program disruption — genes not encoding channels but disrupting synaptic vesicle trafficking, synaptic protein scaffolding, or neuronal signaling cascades:

7. STXBP1 (Munc18-1) — core regulator of SNARE-complex-mediated synaptic vesicle fusion; haploinsufficiency impairs both excitatory and inhibitory neurotransmitter release, and recent work shows GABAergic/glycinergic and glutamatergic neurons mediate distinct components of the STXBP1 encephalopathy phenotype (PMC10993039).
8. CDKL5 — a kinase important for activity-dependent synaptic maturation and dendritic spine development; loss-of-function impairs neuronal circuit maturation rather than acute channel function.
9. PCDH19 — a cell-adhesion protocadherin; disease mechanism is cellular interference between PCDH19-mutant and wild-type neurons in a mosaic tissue, disrupting normal neuronal patterning/network formation (explaining the unusual female-restricted, mosaicism-dependent inheritance).
10. GNAO1 — disrupted G-protein/cAMP signal transduction affecting neuronal excitability and additionally producing a hyperkinetic movement disorder via basal ganglia circuit dysfunction.

11. ARX — transcription factor controlling GABAergic interneuron migration/differentiation during cortical development; disease mechanism is fundamentally a developmental/migrational one rather than acute channel dysfunction, explaining the ARX phenotypic spectrum from lissencephaly to isolated epilepsy.

12. Beyond channelopathy/synaptopathy mechanisms reviewed in PMC11763800 include impaired neurogenesis, disrupted dendrite/axon growth, and (for a subset of genes, e.g., mTOR-pathway-adjacent genes in focal cortical dysplasia-associated DEEs) mTOR pathway hyperactivation driving abnormal cortical lamination and cytomegalic neurons — though the classic mTORopathies (TSC1/2, DEPDC5, mTOR) are more commonly discussed under focal/structural epilepsy overlap than "pure" genetic DEE.

Causal chain (generalized): germline variant → altered channel/synaptic-protein function (loss-of-function, gain-of-function, or dominant-negative) → cell-type-specific dysfunction (interneuron hypoexcitability in Dravet; pyramidal hyperexcitability in SCN2A/SCN8A-GOF; synaptic vesicle release failure in STXBP1) → network-level excitation/inhibition imbalance and/or disrupted circuit maturation → clinical seizures and, in parallel, independently → impaired synaptic plasticity/neurodevelopment → intellectual disability/developmental regression (the "two-hit," partially seizure-independent model that distinguishes DEE nosologically from simple "epilepsy with comorbid ID").

Suggested GO terms: GO:0034765 (regulation of ion transmembrane transport), GO:0007268 (chemical synaptic transmission), GO:0051966 (regulation of synaptic transmission, glutamatergic), GO:0032228 (regulation of synaptic transmission, GABAergic), GO:0016082 (synaptic vesicle priming), GO:0007399 (nervous system development). Suggested CL terms: CL:0000617 (GABAergic interneuron), CL:0002608 (GABAergic neuron), CL:0000679 (glutamatergic neuron), CL:0000598 (pyramidal neuron), CL:0000359 (vasoinhibitory... [n/a]) — specifically CL:0002608 and CL:0000617 for interneuron-selective mechanisms (SCN1A), and CL:0000679/CL:0000598 for excitatory-neuron-predominant mechanisms (SCN2A/SCN8A gain-of-function).

Molecular profiling / advanced technologies: iPSC-derived neuron models are increasingly used to directly compare gain- vs. loss-of-function electrophysiological phenotypes at the patient-variant level (e.g., SCN2A iPSC-neuron studies distinguishing GOF vs. LOF firing patterns — bioRxiv 2023.02.14.528217); single-cell and circuit-level mouse studies (e.g., early postnatal CA3 hippocampal hyperexcitability in SCN2A-DEE mouse models — bioRxiv 2025.06.29.661458) are elucidating developmental-stage-specific circuit mechanisms.

7. Anatomical Structures Affected

• Organ level: primary organ is the brain/CNS (UBERON:0000955). Secondary/systemic involvement is largely a consequence of severe neurological disease: gastrointestinal (feeding difficulties, gastroesophageal reflux — often requiring gastrostomy), musculoskeletal (scoliosis from hypotonia/immobility), respiratory (aspiration pneumonia, a leading non-SUDEP cause of death), and cardiac (some genes, e.g., SCN1A/SCN8A/SCN1B, implicate cardiac Na⁺ channel cross-reactivity as a plausible SUDEP mechanism given shared channel biology).
• Body systems: primarily nervous system; secondarily digestive, respiratory, musculoskeletal, and in movement-disorder-associated genes (GNAO1, ARX), the basal ganglia motor system.
• Tissue/cell level: cerebral cortex (particularly interneuron populations, UBERON:0000956), hippocampus (UBERON:0002421 — a key epileptogenic focus in Dravet and SCN2A models), and thalamocortical circuits. Cell populations: GABAergic interneurons (CL:0000617/CL:0002608 — Nav1.1-dependent), glutamatergic pyramidal neurons (CL:0000598), and to a lesser extent astrocytes (documented astrocyte remodeling in Dravet mouse models — see model organism section).
• Subcellular level: plasma membrane ion channels and channel complexes (GO:0034705 ion channel complex), presynaptic active zone/SNARE machinery (relevant to STXBP1), postsynaptic density/NMDA and GABA-A receptor complexes.
• Localization (UBERON): cerebral cortex (UBERON:0000956), hippocampus (UBERON:0002421), basal ganglia (UBERON:0002420, relevant to GNAO1), and more diffusely, whole brain (UBERON:0000955) given the typically generalized/multifocal nature of most genetic DEEs (contrasted with focal structural epilepsies).
• Lateralization: typically bilateral/generalized dysfunction, consistent with a diffuse channelopathy/synaptopathy mechanism rather than a focal lesion, though EEG can show multifocal or shifting focal features (especially in KCNQ2-DEE and EIMFS-type presentations).

8. Temporal Development

• Onset: ranges from neonatal (first days–weeks of life: KCNQ2, STXBP1, SCN2A/SCN8A-GOF, GNAO1, GRIN1) through early infantile (weeks–months: SCN1A/Dravet syndrome, typically 5–8 months; CDKL5, typically <4 months) to later infancy/early childhood (PCDH19, typically 6–36 months). Onset pattern is usually acute/subacute at the seizure level but the developmental impairment component can be insidious, sometimes preceding recognized seizures.
• Progression: Disease "stages" are not formally codified in oncology-style staging systems but are conventionally described by evolving electroclinical syndrome — e.g., a Ohtahara-syndrome-like (burst-suppression) neonatal presentation evolving into West-syndrome-like infantile spasms/hypsarrhythmia, which may further evolve into a Lennox-Gastaut-syndrome-like multi-seizure-type pattern in later childhood — the so-called "epileptic encephalopathy continuum" (PubMed 35951482, "genetic heterogeneity to phenotypic continuum"). Progression rate is gene- and variant-dependent, ranging from rapidly severe (early-infantile SCN2A/SCN8A-GOF) to more indolent (later-onset, milder allelic series of the same genes).
• Course pattern: most genetic DEEs are chronic and static-to-progressive rather than truly relapsing-remitting, though PCDH19 and Dravet syndrome show a distinctive episodic/clustering seizure pattern layered on a chronic developmental trajectory. A notable and clinically important pattern (well documented in KCNQ2-DEE) is seizure remission with persistent cognitive impairment — i.e., seizure control does not track with developmental outcome, a defining conceptual feature separating "epileptic" from "developmental" components of DEE.
• Remission: spontaneous partial seizure remission is well described in KCNQ2-DEE (~73% eventual seizure freedom) and in some PCDH19 cases (seizure clusters typically diminish in adolescence); developmental impairment is far less likely to remit.
• Critical periods: the first 1–2 years of life are widely regarded as a critical developmental window where uncontrolled seizure activity may compound genetically-driven synaptic/circuit disruption — the rationale underlying "time is brain" arguments for rapid genetic diagnosis and early precision-guided treatment.

9. Inheritance and Population

Epidemiology. A large, prospective, population-based cohort (Scottish national cohort) found DEE incidence of 169 per 100,000 live births (≈1 in 590), with a point prevalence of 112 per 100,000 children (PMC10065214 / PMID:36581463, "Epidemiology of Developmental and Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children"). Related cohort work reports the adjusted incidence of epilepsies presenting in the first 3 years of life at 239 per 100,000 live births, early-infantile DEE (onset <3 months) at ~10/100,000 live births, infantile epileptic spasms syndrome at 58.2/100,000 (≈1 in 1,700), and early myoclonic-atypical-spasms-type presentations at 16.4/100,000 (≈1 in 6,100). SCN1A/Dravet syndrome alone has an expected population frequency of ≥1:20,000.

Inheritance pattern: overwhelmingly autosomal dominant, de novo for the most common genes (SCN1A, STXBP1, SCN2A, KCNQ2, SCN8A, GNAO1, GRIN2B); X-linked for CDKL5, PCDH19, ARX, FOXG1 (with PCDH19 uniquely affecting heterozygous females and sparing hemizygous males via cellular interference); rare autosomal recessive forms exist for a subset of genes (e.g., some metabolic/glycosylation-pathway DEE genes and occasional biallelic presentations).

Penetrance: generally high/complete for the classic de novo dominant channelopathy genes, though variable expressivity is substantial (e.g., the SCN2A GOF-vs-LOF spectrum, and mild/attenuated allelic KCNQ2 phenotypes). PCDH19 shows unusual, mosaicism-dependent penetrance — affected heterozygous females vs. unaffected hemizygous male carriers.

Expressivity: highly variable, both within a gene (allelic series, e.g., SCN2A/SCN8A/KCNQ2 spanning benign familial neonatal epilepsy at the mild end to severe neonatal-onset DEE at the severe end) and even for identical or similar variants — supporting a role for genetic background/modifier effects.

Genetic anticipation: not a recognized feature of the major DEE genes (which are not repeat-expansion disorders); not applicable to this class as currently understood.

Germline mosaicism: documented and clinically important for recurrence-risk counseling — an apparently de novo variant in a proband carries a residual (several-percent) sibling recurrence risk due to unrecognized parental germline mosaicism, and is specifically well-described for SCN1A and other DEE genes.

Founder effects: not prominently described for most DEE genes (mutations arise recurrently de novo rather than being inherited from a founder population), though certain recurrent hotspot variants (e.g., specific KCNQ2 missense positions) recur across unrelated families due to mutational hotspot biology rather than shared ancestry.

Consanguinity: relevant primarily to the minority of autosomal recessive DEE genes; increases pretest probability for biallelic causes in consanguineous families.

Carrier frequency: not typically applicable to de novo dominant disease; relevant mainly for recessive DEE genes and for PCDH19 male carriers (who are unaffected transmitters).

Population demographics: No strong, well-replicated ethnic/geographic enrichment has been established for the major genetic DEEs as a class (contrast with some single-gene metabolic disorders); ascertainment is affected by access to genetic testing, so reported incidence is likely an underestimate in regions with limited NGS access. Sex ratio is roughly equal for autosomal dominant genes but strongly skewed by X-linked genes (CDKL5 and PCDH19 predominantly affect females; ARX/FOXG1-related phenotypes show sex-specific presentations). Age distribution is concentrated in infancy/early childhood at diagnosis, with increasing recognition of an adult DEE population as the first generation of genetically diagnosed infants ages into adulthood.

10. Diagnostics

Clinical/EEG tests: interictal and ictal EEG (burst-suppression pattern, hypsarrhythmia, multifocal epileptiform discharges), video-EEG for seizure semiology characterization, brain MRI (to exclude structural causes and to identify secondary structural changes such as diffuse atrophy), and in selected cases, metabolic screening (plasma amino acids, urine organic acids, CSF neurotransmitters, biotinidase, pyridoxine/pyridoxal-5-phosphate trial) to exclude treatable metabolic DEE mimics (a critical step before committing to a purely "genetic, non-treatable-metabolic" workup).

Genetic testing. Current consensus favors early, first-line genome-wide sequencing (WES or WGS, often as a rapid trio test) over sequential single-gene or small panel testing, given the extreme genetic heterogeneity (>900 genes): - WES as first-line has been directly studied and validated as an efficient first-tier test in DEE cohorts, with diagnostic yields commonly cited around 35–43% (PMC10816140, "Whole Exome Sequencing as a First-Line Molecular Genetic Test in DEE"; PubMed 35701389). - Targeted gene panels remain in use where WES/WGS access is limited, with lower diagnostic yield in comparative studies (e.g., ~22% panel vs. higher WES yield in a Turkish cohort — PMC12562696); panels risk missing genes not yet included and non-coding/structural variants. - Chromosomal microarray (CMA) remains indicated to detect CNVs not well captured by exome sequencing, particularly for genes like CDKL5/ARX in the Xp22 region. - Trio sequencing (proband + both parents) substantially improves variant interpretation by enabling direct de novo confirmation, which is often the single strongest piece of evidence for pathogenicity in this de novo-dominant-predominant disease class. - RNA sequencing / functional follow-up is increasingly used to resolve splicing VUS. - Mitochondrial DNA and repeat-expansion testing are reserved for specific clinical phenotype overlaps (mitochondrial DEE mimics, and repeat-expansion disorders are not typically part of the core genetic DEE gene set).

Clinical diagnostic criteria: the ILAE 2022 operational framework for diagnosing DEE requires (1) epilepsy (recurrent unprovoked seizures) plus (2) developmental impairment attributable to the epilepsy/epileptiform activity and/or the underlying etiology, assessed against age-appropriate developmental milestones, with an "operational definition" recently published to standardize trial-eligibility criteria (PMC11997937, Epilepsia 2025, "Operational definition of developmental and epileptic encephalopathies to underpin the design of therapeutic trials").

Differential diagnosis: structural epilepsies (cortical malformations, HIE), metabolic/treatable epileptic encephalopathies (pyridoxine-dependent epilepsy, GLUT1 deficiency, biotinidase deficiency, non-ketotic hyperglycinemia, creatine deficiency syndromes — all of which must be excluded/treated specifically since they are potentially reversible), mitochondrial disorders, and chromosomal syndromes with epilepsy as a feature.

Screening: no population newborn-screening program currently exists for genetic DEE (unlike some single-gene metabolic disorders); rapid genomic sequencing in the NICU/PICU setting for infants presenting with early-life refractory seizures functions as a de facto early-detection strategy. Cascade/carrier screening is relevant mainly for the recessive and X-linked forms.

11. Outcome/Prognosis

Mortality: genetic DEEs carry markedly elevated premature mortality. A large cohort study of people with genetic DEEs reported 42/510 deaths (8%), a mortality rate of 6.1 per 1,000 person-years, of which SUDEP accounted for 19/42 deaths (48%) — the leading identifiable cause (Neurology 2023, "Rates of Status Epilepticus and Sudden Unexplained Death in Epilepsy in People With Genetic Developmental and Epileptic Encephalopathies," PMC10115508). A meta-analysis of randomized trial/extension-study populations estimated an overall SUDEP rate of ~4.3 per 1,000 person-years and overall mortality of ~8.8 per 1,000 person-years across DEE trial cohorts, with SUDEP risk highest in Dravet syndrome and comparatively lower (but still substantial) in Lennox-Gastaut syndrome and infantile epileptic spasms syndrome (Epilepsia 2025 meta-analysis, "SUDEP and mortality in developmental and epileptic encephalopathies"). For Dravet syndrome specifically, mortality is reported at 15–20%, with 73% of deaths before age 10 and ~93% before age 20; SUDEP accounts for ~49% of Dravet deaths. Non-SUDEP causes of death include status epilepticus, aspiration pneumonia, and seizure-related accidental injury/drowning. Early mortality is also specifically documented in STXBP1-related disorders (PMC11828786).

Morbidity/function: the majority of survivors have lifelong, severe intellectual disability, motor impairment, and behavioral/psychiatric comorbidity (autism, ADHD, anxiety) as described in the Phenotypes section; functional independence in adulthood is rare for the most severe gene-associated forms (CDKL5, STXBP1, early-infantile SCN2A/SCN8A-GOF), while some milder allelic variants (later-onset KCNQ2, some PCDH19) permit partial functional independence.

Complications: status epilepticus, aspiration pneumonia (a leading non-SUDEP cause of death), fractures/injury from seizures or falls, scoliosis, feeding/nutritional failure requiring gastrostomy, and psychiatric comorbidity requiring dedicated management.

Prognostic factors: earlier seizure onset is generally associated with worse cognitive outcome (documented specifically in PCDH19, where early onset correlates with disease severity); the specific causal gene and variant type (gain- vs loss-of-function) strongly predicts both seizure course and treatment responsiveness; achievement of early seizure control is associated with (though not fully protective against) better developmental trajectory.

12. Treatment

Pharmacotherapy — general antiseizure medications (ASMs): broad-spectrum ASMs (valproate, clobazam, topiramate, levetiracetam, lamotrigine, rufinamide, felbamate, lacosamide, vigabatrin) are used empirically, often in combination, given high rates of pharmacoresistance. Critical gene-specific contraindication: sodium-channel-blocking ASMs (phenytoin, carbamazepine, oxcarbazepine, lamotrigine at high dose) can worsen seizures in SCN1A loss-of-function Dravet syndrome and are generally avoided, while the same drug class can be beneficial in SCN2A/SCN8A gain-of-function DEE — a textbook example of genotype-guided precision prescribing in this disease class.

Recently approved/DEE-specific pharmacotherapies: - Stiripentol — potentiates GABAergic transmission; approved as adjunct for Dravet syndrome. - Cannabidiol (Epidiolex) — FDA/EMA-approved for Dravet syndrome and Lennox-Gastaut syndrome. - Fenfluramine — serotonergic/sigma-1-receptor agonist mechanism; approved for Dravet syndrome and, more recently, CDKL5 deficiency disorder and Lennox-Gastaut syndrome. All three are highlighted as effective, well-tolerated additions to the DEE armamentarium (tandfonline review; DelveInsight pipeline overview). - ACTH/oral corticosteroids — mainstay for infantile-spasms-type presentations regardless of underlying gene.

Pharmacogenomics: the SCN1A/SCN2A/SCN8A gain-of-function vs. loss-of-function dichotomy described above is the clearest example of pharmacogenomic decision-making currently in DEE clinical practice; cenobamate has recently been explored as an add-on for SCN8A-DEE specifically (medRxiv 2024.10.17.24312949).

Advanced therapeutics (investigational/emerging): - Antisense oligonucleotide (ASO) therapy: an SCN1A-upregulating ASO strategy (targeting a non-productive splice isoform to boost productive SCN1A transcript and restore Nav1.1 haploinsufficiency) has entered clinical development for Dravet syndrome; conversely, an SCN2A-lowering ASO strategy has been studied preclinically for SCN2A gain-of-function DEE (bioRxiv 2020.09.09.289900, "Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsy"). - Gene therapy: AAV-mediated gene-replacement/upregulation strategies are in preclinical-to-early-clinical development for Dravet syndrome (SCN1A upregulation via engineered transcription factors) and other haploinsufficiency genes (e.g., STXBP1, SCN1A). - Base editing: an adenine base editor packaged in dual AAVs (SCN8A-ABE) corrected a gain-of-function SCN8A variant and significantly increased survival and reduced/eliminated seizures in a mouse model, illustrating a genome-editing path toward curative therapy (PMC12871382).

Surgical/interventional: vagus nerve stimulation (VNS) is used in selected drug-resistant DEE patients, including gene-specific case reports (e.g., KCNB1-DEE — PMC12446608) and studied in young children specifically (PMC10624125); corpus callosotomy for drop attacks; focal resective surgery is rarely applicable given the typically diffuse/genetic (non-focal-lesional) substrate, but may be considered when a coexisting focal structural abnormality (e.g., focal cortical dysplasia) is identified.

Supportive/rehabilitative care: ketogenic diet has demonstrated efficacy across multiple DEE subtypes and is a well-established non-pharmacological cornerstone (PMC12358386, "Progress of ketogenic diet in the treatment of developmental epileptic encephalopathy"); physical/occupational/speech therapy, nutritional support (including gastrostomy), and multidisciplinary developmental support are standard.

Suggested MAXO terms: MAXO:0000647 (chemotherapy — n/a here), MAXO:0000088 (dietary intervention — ketogenic diet), MAXO:0000011 (physical therapy), MAXO:0001017 (vaccination — n/a), MAXO:0000004 (surgical procedure — VNS/callosotomy), MAXO:0001001 (gene therapy), MAXO:0000950 (supportive care). Pharmacotherapy entries would use NCIT:C15986 (Pharmacotherapy) with therapeutic_agent bound to CHEBI (e.g., cannabidiol, stiripentol, fenfluramine) or NCIT drug-class terms.

Treatment outcomes: response rates vary widely by gene and drug; adverse events for the newer agents include appetite/weight changes and cardiac monitoring requirements for fenfluramine (historical cardiac-valvulopathy concerns from its earlier obesity-drug formulation, now mitigated by low-dose, monitored DEE use), sedation for cannabidiol/clobazam combinations, and hepatotoxicity monitoring for valproate/stiripentol/felbamate combinations.

13. Prevention

Primary prevention: not currently possible in the traditional sense (no way to prevent de novo mutation occurrence); the closest analog is avoidance of known seizure triggers (fever management, sleep hygiene) in already-diagnosed patients to reduce secondary seizure-related morbidity, and avoidance of contraindicated sodium-channel-blocking ASMs in SCN1A-Dravet syndrome to prevent iatrogenic seizure worsening.

Secondary prevention: early genetic diagnosis enabling gene-informed ASM selection (the sodium-channel-blocker example above) functions as a form of secondary prevention of avoidable seizure exacerbation and status epilepticus.

Genetic counseling: central to management — recurrence-risk counseling for parents (typically low but non-zero due to germline mosaicism, as discussed above), and reproductive options (preimplantation genetic diagnosis, prenatal testing) once a familial pathogenic variant is identified.

Screening/early detection: no population-level newborn screening program exists for genetic DEE; rapid/ultra-rapid genomic sequencing for critically ill infants with early-life seizures functions as the practical "early detection" pathway, enabling faster gene-informed management.

Prophylaxis: SUDEP-risk-reduction counseling (nocturnal supervision/monitoring devices, seizure-alert systems, optimized seizure control) is a key preventive intervention given the high SUDEP burden documented above; some centers discuss rescue-medication protocols (e.g., benzodiazepine rescue therapy) as prophylaxis against prolonged seizures/status epilepticus.

14. Other Species / Natural Disease

Naturally occurring DEE-like disease in companion animals is not well characterized as a direct ortholog of any single human genetic DEE (unlike, e.g., some canine epilepsy loci); OMIA does list canine idiopathic epilepsy loci, but a documented natural-disease parallel specific to SCN1A/STXBP1/etc. orthologs in domestic species was not identified in this search pass. Orthologous genes are highly conserved across vertebrates (Scn1a, Stxbp1, Scn2a, Kcnq2, Cdkl5, Pcdh19, Gnao1, Arx all have well-annotated mouse, rat, and zebrafish orthologs per NCBI Gene/Alliance of Genome Resources), which underpins the extensive model-organism literature below. No zoonotic or cross-species transmission relevance applies, as this is a non-infectious monogenic disease class.

15. Model Organisms

Model systems are extensively used and are reviewed comparatively in PMC8547712, "Overlaps, gaps, and complexities of mouse models of Developmental and Epileptic Encephalopathy".

Mouse models: - Scn1a⁺/⁻ (Dravet syndrome) mice — the best-characterized DEE model; recapitulate spontaneous seizures, premature/SUDEP-like mortality, hyperactivity, social-interaction deficits, and cognitive impairment beginning around the second–third postnatal week, closely paralleling the human Nav1.1-interneuron-hypoexcitability mechanism. Genetic-rescue studies (Scn1a reactivation after symptom onset) have shown reversal of pathological phenotypes, supporting gene-therapy feasibility (Nature Communications 2021, PMID via doi:10.1038/s41467-021-27837-w). Astrocyte remodeling has also been documented as a longer-lasting pathological feature in this model (bioRxiv 2026.01.06.697745). - Scn2a knock-in mice (e.g., p.A263V gain-of-function variant knocked into the endogenous locus) — show increased persistent Na⁺ current in heterologous expression and spontaneous generalized tonic-clonic seizures in vivo, confirming gain-of-function mechanism and enabling early postnatal circuit-level study of CA3 hippocampal hyperexcitability (bioRxiv 2025.06.29.661458). A separate Scn2a knockout (haploinsufficiency) model shows an autistic-like phenotype attenuated with age, modeling the loss-of-function end of the SCN2A allelic spectrum (PMC6733925). - Scn1b (Na⁺ channel β1 subunit) mice — model human SCN1B-linked DEE, reproducing both epilepsy and SUDEP (PMC10903178). - Scn8a mutation-associated models — used to test base-editing correction (SCN8A-ABE), with AAV-delivered adenine base editing improving survival and reducing/eliminating seizures (PMC12871382). - Gabrg2 knock-in mice — model GABRG2-related epileptic encephalopathy, showing spontaneous generalized seizures and cognitive impairment, directly linking GABA-A receptor dysfunction to the DEE phenotype (PMC12501280).

iPSC-derived neuron / cellular models: patient-derived iPSC neurons carrying gain-of-function vs. loss-of-function SCN2A variants show distinctive, mechanism-concordant electrophysiological phenotypes in vitro, supporting the model's utility for genotype-specific mechanism dissection and drug screening (bioRxiv 2023.02.14.528217).

Model characteristics/limitations: mouse models generally recapitulate core seizure phenotypes and premature mortality well, and increasingly reproduce behavioral/cognitive comorbidities, but the PMC8547712 review specifically emphasizes gaps and overlaps — i.e., not all mouse models fully capture the human developmental-regression component, genetic background strongly modifies phenotype severity/penetrance (complicating cross-model comparison), and species differences in interneuron subtype proportions and network architecture limit direct translational inference for cognitive/behavioral endpoints. iPSC-neuron models, while capturing cell-autonomous electrophysiology well, lack the multicellular network and whole-organism developmental context needed to model the "developmental" component of DEE.

Applications: these models are used for (1) mechanistic dissection (channelopathy vs. synaptopathy, GOF vs. LOF), (2) precision-therapy validation (genotype-matched sodium-channel-blocker response), and (3) advanced-therapeutic proof-of-concept (ASO, gene therapy, base editing) prior to human trials, as detailed in the Treatment section above.

Resources: MGI (Mouse Genome Informatics) for Scn1a/Scn2a/Stxbp1/Kcnq2/Cdkl5 alleles; IMPC/KOMP for systematic knockout phenotyping; ZFIN for zebrafish scn1lab Dravet models (an additional model system not detailed above but widely used for high-throughput drug screening in Dravet syndrome).

Summary of Key Ontology-Term Suggestions for KB Curation

• MONDO: MONDO:0010246 (umbrella "developmental and epileptic encephalopathy" grouping term, OMIM PS308350) plus individual gene-specific MONDO IDs per subtype.
• HP terms: HP:0032900 (Seizure), HP:0011097 (Epileptic spasm), HP:0001263 (Developmental delay), HP:0002376 (Developmental regression), HP:0001249 (Intellectual disability), HP:0010851 (EEG with burst suppression), HP:0000729 (Autistic behavior), HP:0004328 (Hand stereotypies), HP:0010984 (Digenic inheritance — n/a here but relevant framework), HP:0001252 (Hypotonia).
• GO terms: GO:0034765, GO:0007268, GO:0051966, GO:0032228, GO:0016082, GO:0007399.
• CL terms: CL:0000617, CL:0002608 (GABAergic interneuron), CL:0000679, CL:0000598 (glutamatergic/pyramidal neuron).
• UBERON terms: UBERON:0000955 (brain), UBERON:0000956 (cerebral cortex), UBERON:0002421 (hippocampus), UBERON:0002420 (basal ganglia).
• MAXO terms: MAXO:0000088 (dietary/ketogenic diet), MAXO:0000011 (physical therapy), MAXO:0000004 (surgical procedure — VNS), MAXO:0001001 (gene therapy).
• CHEBI terms (representative drugs): cannabidiol, fenfluramine, stiripentol, valproate, clobazam.

Curation Note on Scope

Given dismech's schema conventions, "Genetic Developmental and Epileptic Encephalopathy" is best modeled either as (a) an umbrella Grouping (analogous to Mucopolysaccharidoses or Digenic_and_Oligogenic_Disorders) with grouping_basis: SHARED_MECHANISM/SHARED_PHENOTYPE pointing down to individual gene-defined member entries (SCN1A-Dravet syndrome, STXBP1-DEE, SCN2A-DEE, KCNQ2-DEE, CDKL5 deficiency disorder, PCDH19-clustering epilepsy, etc. — several of which likely already exist or should be created as standalone Disease entries), each conforming to the existing epilepsy_excitation_inhibition_imbalance mechanism module for the shared excitation/inhibition-imbalance convergence point; or (b) if the KB intends a single entry for the umbrella concept itself, it should be scoped narrowly to the shared definitional/diagnostic/epidemiological content above, with gene-specific pathophysiology, evidence, and precision-therapy detail deferred to the individual gene-level entries — consistent with the "lump vs. split" design guidance in this repository's decision register.

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Genetic Developmental and Epileptic Encephalopathy
• MONDO ID: (if available)
• Category: Genetic

Research Objectives

Please provide a comprehensive research report on Genetic Developmental and Epileptic Encephalopathy covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Genetic Developmental and Epileptic Encephalopathy

Executive summary and scope

Genetic developmental and epileptic encephalopathies (genetic DEEs) are not one molecular disease but an etiologically heterogeneous family of severe neurodevelopmental epilepsies. The defining concept is that both the underlying developmental disorder and epileptic activity contribute—independently and additively—to cognitive, behavioral, and neurological impairment. They usually begin in infancy or childhood with seizures, abundant epileptiform EEG activity, developmental slowing or regression, and multiple non-seizure comorbidities. The International League Against Epilepsy (ILAE) introduced the combined term in 2017 to distinguish DEE from a purely “epileptic encephalopathy,” in which epileptic activity is assumed to be the principal cause of developmental deterioration. (scheffer2024developmentalandepileptic pages 1-4, chang2023genetictestingin pages 4-6)

A 2024 expert review describes DEEs as the most severe epilepsy group and emphasizes that management must address seizures, development, behavior, movement, sleep, feeding, respiratory health, and family burden—not seizure counts alone. More than 800–900 genes have been associated with monogenic DEEs, although gene validity and phenotype specificity vary and the number continues to expand. (specchio2024theexpandingfield pages 1-6, scheffer2024developmentalandepileptic pages 9-11, scheffer2024developmentalandepileptic pages 19-21)

Evidence boundary: statistics from Dravet syndrome, CDKL5 deficiency disorder, STXBP1 encephalopathy, infantile epileptic spasms syndrome, or another named DEE must not automatically be generalized to all genetic DEEs.

1. Disease information

Definition, names, and identifiers

Common names include developmental and epileptic encephalopathy, DEE, genetic DEE, developmental epileptic encephalopathy, and the older terms epileptic encephalopathy and early infantile epileptic encephalopathy. Named syndromes within the umbrella include Dravet syndrome, early-infantile DEE, epilepsy of infancy with migrating focal seizures, infantile epileptic spasms syndrome, and Lennox–Gastaut syndrome; some are genetically homogeneous, whereas others have structural, metabolic, infectious, or unknown causes. (scheffer2024developmentalandepileptic pages 9-11, scheffer2024developmentalandepileptic pages 1-4)

There is no single universal OMIM number, because OMIM generally assigns entries to individual gene-defined disorders such as SCN1A-, KCNQ2-, STXBP1-, or CDKL5-related encephalopathy. The same limitation applies to Orphanet and MONDO: individual syndromes have specific identifiers, while the umbrella concept is represented hierarchically and database mappings can change. For production use, the current MONDO/Orphanet release should therefore be queried rather than assigning one unverified umbrella identifier. ICD-10-CM usually requires epilepsy/syndrome and intellectual-disability codes rather than a unique genetic-DEE code; ICD-11 provides more granular developmental/epileptic encephalopathy categories. MeSH concepts include Epileptic Encephalopathies and individual syndromes.

The evidence summarized here is primarily aggregated disease-level evidence from reviews, cohorts, registries, and trials. It is not an extraction from individual EHRs, although several cohorts were assembled by retrospective medical-record and EEG review.

2. Etiology, risk, protective factors, and gene–environment interaction

Causal factors

Genetic DEEs arise from germline or post-zygotic pathogenic variants affecting neuronal excitability, synaptic transmission, neurotransmitter receptors, cortical development, intracellular signaling, metabolism, organelle function, and chromatin/transcriptional regulation. Representative genes include:

• Ion channels: SCN1A, SCN2A, SCN8A, KCNQ2, KCNT1, KCNH5, CACNA1A.
• Synaptic release/signaling: STXBP1, SYNGAP1, PCDH19, NBEA.
• Receptors: GRIN family genes.
• mTOR/cortical development: TSC1, TSC2, MTOR, DEPDC5.
• Chromatin/transcription/RNA regulation: CHD2, HNRNPU, KMT2A, CDKL5.
• Metabolic/transport pathways: SLC2A1, GLDC and numerous mitochondrial or vitamin-responsive disorders.

In a 2024 early-onset cohort, ion-channel genes were the largest functional class, accounting for 36/104 monogenic cases; SCN1A and KCNQ2 were the leading channel genes. (cavirani2024geneticepilepsiesand pages 2-4, cavirani2024geneticepilepsiesand pages 4-6)

Genetic risk and inheritance

Most diagnosed severe early-onset cases involve highly penetrant rare variants rather than common polygenic susceptibility. De novo autosomal-dominant variants are prominent, but autosomal-recessive, X-linked, mitochondrial, inherited dominant, and parental-mosaic mechanisms occur. A 2024 Italian survey of 1,568 molecularly diagnosed patients found 77% involving autosomal-dominant genes, 17% X-linked genes, and 6% autosomal-recessive genes; SCN1A accounted for 16%, KCNQ2 5.6%, and SCN2A 5%. These figures reflect diagnosed cases and testing practice, not unbiased population frequencies.

Recurrence risk is variant-specific. A confirmed de novo variant usually implies low—but not zero—recurrence because parental germline mosaicism is possible. Recessive disease creates a 25% recurrence risk for each pregnancy when both parents are carriers. X-linked recurrence depends on maternal carrier or mosaic status. Variable expressivity and incomplete penetrance occur in several genes, particularly familial channel, synaptic, and mTOR-pathway disorders. Genetic anticipation is not a general DEE feature.

Pathogenic variants are usually absent or extremely rare in population databases such as gnomAD; a numerical allele-frequency threshold cannot be assigned across the umbrella. Classification must follow ACMG/AMP criteria using segregation, population frequency, phenotype match, computational data, and functional evidence. Missense, nonsense, frameshift, splice, copy-number, structural, regulatory, mitochondrial, and mosaic variants all occur. A VUS is not diagnostic and should not independently direct irreversible therapy. Exome studies can report VUS rates of 25.3–86%, illustrating the interpretation burden. (chang2023genetictestingin pages 4-6)

Environmental and protective factors

There is no evidence that smoking, diet, pollution, occupation, or an infectious agent is a primary cause of genetic DEE. Fever, infection, sleep loss, and elevated temperature can trigger seizures in susceptible genotypes, especially SCN1A-related Dravet syndrome; inflammation may worsen SCN1A channel dysfunction and seizure severity. This is trigger modulation, not causation. Routine vaccination does not create the underlying genetic disorder, although fever temporally associated with vaccination can unmask fever-sensitive seizures. (specchio2024theexpandingfield pages 14-17)

No broadly validated environmental or genetic protective factor prevents genetic DEE. Prompt fever management, avoidance of known individual triggers, medication adherence, nocturnal supervision where appropriate, and early syndrome-specific treatment may reduce complications. Ketogenic dietary therapy can improve seizures in subsets but is treatment, not primary prevention. Model-organism observations such as estrogen-mediated suppression of CNTNAP2-associated behaviors are hypothesis-generating and not established human protective factors. (sun2024strategiesfordissecting pages 14-15)

3. Phenotypes

Core and associated phenotypes vary by gene and age:

• Recurrent seizures—often neonatal or infantile onset, multiple types, prolonged, and drug-resistant. Suggested HPO: Seizure (HP:0001250), Neonatal-onset seizures, Infantile-onset seizures, Status epilepticus, Epileptic spasm.
• Abnormal EEG—multifocal or generalized epileptiform discharges; syndrome-dependent hypsarrhythmia, burst suppression, slow spike-wave, or migrating focal activity. HPO: EEG abnormality (HP:0002353), Hypsarrhythmia.
• Global developmental delay/intellectual disability, frequently severe or profound; development may be delayed before seizures and may stagnate or regress after seizure onset. HPO: HP:0001263, HP:0001249, Developmental regression (HP:0002376).
• Speech/language impairment, sometimes minimal or absent speech. HPO: Delayed speech and language development (HP:0000750), Absent speech.
• Motor abnormalities: hypotonia, spasticity, ataxia, gait impairment, dystonia, stereotypies, tremor, and myoclonus. HPO: HP:0001252, HP:0001257, HP:0001251, HP:0001332, HP:0002072.
• Behavioral/psychiatric features: autism traits, ADHD, irritability, anxiety, and sleep disturbance. HPO: HP:0000729, HP:0007018, HP:0002360.
• Systemic morbidity: feeding/swallowing and gastrointestinal problems, respiratory vulnerability, orthopedic complications, visual impairment, and growth abnormalities, depending on genotype. (scheffer2024developmentalandepileptic pages 9-11, scheffer2024developmentalandepileptic pages 1-4)

In a 2024 multicenter monogenic cohort, developmental delay/intellectual disability occurred in 84/104 (80.7%), abnormal neurological examination in 74/104 (71%), autistic features in 12/104 (11.5%), ADHD in 4/104 (3.8%), and other behavioral disorders in 15/104 (14.4%). These are cohort—not universal—frequencies. Seizures began at a mean 11 months, with generalized onset in 37.5% and focal onset in 31%. (cavirani2024geneticepilepsiesand pages 2-4, cavirani2024geneticepilepsiesand pages 4-6)

Among 77 patients selected for movement disorders, stereotypies occurred in 48%, dystonia in 44%, chorea in 23%, myoclonus in 18%, ataxia in 12%, tremor in 9%, and hypokinesia in 8%; 47% had more than one movement disorder. Selection makes these inappropriate as general DEE prevalence estimates.

Quality of life is substantially impaired by seizures, medication adverse effects, mobility, communication limitations, behavior, sleep, and dependence in activities of daily living. Cross-sectional studies show worse health-related quality of life than both the general population and unselected childhood epilepsy cohorts. Caregiver depression, employment disruption, and family burden are substantial. (scheffer2024developmentalandepileptic pages 17-19)

4. Genetic and molecular information

Table: This table summarizes major mechanistic categories represented in genetic developmental and epileptic encephalopathies, linking gene classes to variant effects, disease biology, and current precision-management implications. It is useful as a compact knowledge-base scaffold because DEE is genetically heterogeneous and treatment logic often depends on variant-specific gain- versus loss-of-function.

The crucial annotation principle is variant-specific functional direction. For example, pathogenic variants in sodium-channel genes may cause loss of function, gain of function, or altered gating. The appropriate therapy can therefore be opposite for different variants or genes: suppressing sodium current may help some gain-of-function channelopathies but worsen SCN1A loss-of-function Dravet syndrome. (specchio2024theexpandingfield pages 6-8, scheffer2024developmentalandepileptic pages 19-21)

Most causal variants are constitutional germline changes, but post-zygotic mosaic variants—especially in cortical-development/mTOR genes—may be restricted to brain tissue and missed in blood. Chromosomal abnormalities and CNVs are important: in one 168-person early-onset cohort, 45 pathogenic/likely pathogenic diagnoses were chromosomal/CNV disorders and 104 were monogenic. (cavirani2024geneticepilepsiesand pages 2-4)

Modifier genes and epigenetic state probably help explain variable expressivity, but clinically validated modifier alleles are not available for the umbrella disorder. Epigenetic dysfunction can itself be upstream when causal genes encode chromatin remodelers or transcriptional regulators; a universal DEE methylation signature has not been established.

5. Environmental information

Genetic DEE is neither infectious nor occupational and has no zoonotic transmission. Non-genetic insults—hypoxic–ischemic injury, congenital infection, immune encephalitis, trauma, and toxic-metabolic illness—are instead important differential etiologies for a child with seizures and developmental impairment. Environmental trigger management is individualized; there is no evidence-based universal lifestyle program that reverses the genetic neurodevelopmental defect.

6. Mechanism and pathophysiology

A general causal chain is:

pathogenic variant/CNV → altered protein dosage or function → abnormal neuronal development, excitability, synaptic release, receptor signaling, metabolism, or cortical architecture → impaired excitation–inhibition balance and epileptic networks → recurrent seizures and epileptiform EEG activity → additional activity-dependent disruption of plasticity and cognition, superimposed on the primary developmental defect → developmental slowing/regression and multimorbidity. (scheffer2024developmentalandepileptic pages 1-4, specchio2024theexpandingfield pages 6-8)

Upstream mechanisms include channel dysfunction, synaptic-vesicle defects, receptor dysfunction, mTOR overactivation, metabolic deficiency, and altered chromatin regulation. Downstream mechanisms include network hypersynchrony, excitotoxic/metabolic stress, sleep disruption, medication burden, injury from prolonged seizures, and impaired experience-dependent plasticity.

The developing brain is particularly vulnerable because excitatory AMPA/NMDA receptor composition and inhibitory GABAergic circuits change rapidly in infancy; immature GABAergic currents can remain depolarizing, while accelerated excitatory-circuit maturation can create transient hyperexcitability. (specchio2024theexpandingfield pages 6-8)

Suggested ontology mappings include:

• GO biological processes: regulation of membrane potential (GO:0042391), chemical synaptic transmission (GO:0007268), synaptic vesicle exocytosis (GO:0016079), glutamate receptor signaling pathway, GABAergic synaptic transmission, TOR signaling (GO:0031929), neuron differentiation (GO:0030182), and chromatin organization (GO:0006325).
• Cell Ontology: neuron (CL:0000540), glutamatergic neuron (CL:0000679), GABAergic neuron (CL:0000617), cortical neuron, interneuron, neural progenitor cell, astrocyte, oligodendrocyte, and microglial cell. The principal cell population differs by gene.
• Cellular components: voltage-gated ion-channel complex, presynaptic active zone, synaptic vesicle, postsynaptic density, neuronal plasma membrane, nucleus/chromatin, mitochondrion, lysosome, and mTOR complexes.

Transcriptomic, proteomic, metabolomic, single-cell, and spatial data remain fragmented and gene-specific. Multi-omics is a major research priority, not yet a validated umbrella diagnostic biomarker. (specchio2024theexpandingfield pages 17-21)

7. Anatomical structures affected

The primary organ is the brain, especially distributed cortical and subcortical networks. Depending on genotype, affected structures can include cerebral cortex, hippocampus, thalamus, basal ganglia, cerebellum, and brainstem autonomic/respiratory networks. Suggested UBERON terms include brain (UBERON:0000955), cerebral cortex (UBERON:0000956), hippocampal formation, thalamus, basal ganglion, cerebellum (UBERON:0002037), and brainstem (UBERON:0002298).

MRI can be normal, show nonspecific atrophy, reveal a malformation of cortical development, or demonstrate a syndrome-specific abnormality. In a prospective early-infantile cohort, MRI was abnormal in 35/80; 16/35 had a malformation and 19/35 had nonspecific findings that did not establish etiology. No consistent lateralization characterizes genetic DEE as a group.

Secondary systems include musculoskeletal tissue through immobility/spasticity, gastrointestinal and feeding systems, respiratory/autonomic systems, vision, and sleep regulation. These are usually complications or pleiotropic manifestations rather than the primary lesion.

8. Temporal development

Approximately 75% of DEEs begin before age three, but onset can occur later in childhood. Population-based data show that 27% of DEEs began after age three, warning against restricting testing to infancy. (scheffer2024developmentalandepileptic pages 1-4)

Typical course:

1. Pre-seizure period: normal, subtly delayed, or clearly abnormal development depending on genotype.
2. Seizure onset: neonatal, infantile, or childhood onset; acute presentation but chronic underlying disease.
3. Evolution: multiple seizure types and changing EEG patterns; developmental slowing, plateau, or regression.
4. Chronic phase: seizure burden may improve in some syndromes while intellectual, behavioral, motor, and communication disability persists or becomes more apparent.

In a 10-year SCN1A-positive Dravet study, epilepsy severity became less severe while developmental outcome worsened and autistic, behavioral, and motor/mobility comorbidities became more frequent. This illustrates that seizure improvement does not equal neurodevelopmental recovery. Critical intervention windows probably occur before or soon after network dysfunction begins, supporting rapid diagnosis and early treatment, but exact windows remain gene-specific. (scheffer2024developmentalandepileptic pages 17-19)

9. Inheritance and population epidemiology

A population-based New Zealand study estimated a DEE point prevalence of 112 per 100,000 children and cumulative incidence of 169 per 100,000—approximately 1 in 590 children by age 16. The broader category of epilepsy plus developmental impairment occurred in approximately 1 in 340 children. These figures include genetically unresolved and non-genetic DEEs, not only molecularly confirmed disease. (scheffer2024developmentalandepileptic pages 1-4, scheffer2024developmentalandepileptic pages 19-21)

Syndrome cumulative incidence per 100,000 children was 58.2 for infantile epileptic spasms syndrome, 16.4 for epilepsy with myoclonic-atonic seizures, 13.2 for Lennox–Gastaut syndrome, and 5.1 for Dravet syndrome. One-third of children with DEE lacked a recognized electroclinical syndrome.

In the Italian molecular survey, diagnoses increased more than tenfold from 2012 to 2022; the mean age at molecular diagnosis was 11.2 years despite typically pediatric onset, demonstrating historical diagnostic delay. Geographic and ethnic differences in reported frequency largely reflect ascertainment, consanguinity, founder variants, access to sequencing, and variant interpretation. There is no established universal ethnic predisposition. Sex ratio depends on gene; X-linked disorders and sex-limited PCDH19-related disease can produce marked differences. One population cohort was 58% male, whereas a 2024 early-onset genetic cohort included 97 females and 71 males, arguing against a universal sex ratio.

10. Diagnostics

Clinical evaluation

Diagnosis integrates detailed prenatal/perinatal and three-generation family history, seizure semiology, serial developmental examination, neurological and dysmorphology assessment, video-EEG, brain MRI using an epilepsy protocol, and targeted metabolic testing. EEG confirms epilepsy type and encephalopathic patterns but is rarely gene-specific. MRI identifies malformations, injuries, or structural mimics.

Urgent treatable investigations in neonatal/infantile onset can include glucose, electrolytes, calcium, magnesium, blood gas/lactate, ammonia, liver studies, plasma amino acids, acylcarnitines, urine organic acids, CSF studies where indicated, and therapeutic trials/testing for pyridoxine-, pyridoxal-phosphate-, folinic-acid-, biotin-, or glucose-transporter-responsive disease. In one prospective cohort, metabolic testing was diagnostic in 3/41 tested children, all with biotinidase deficiency; vitamin-responsive disease was the only factor independently associated with better seizure control. This supports urgent testing even though the yield is lower than sequencing.

Genetic workflow

A practical workflow is:

1. Rapid trio genome or exome sequencing for critically ill neonates/infants where available.
2. Otherwise, trio exome/genome or a comprehensive epilepsy/DEE panel with CNV calling.
3. Chromosomal microarray when congenital anomalies, dysmorphism, or CNV disease is suspected, or when sequencing does not provide reliable CNV detection.
4. Mitochondrial genome, repeat-expansion, methylation, RNA, or biochemical testing when phenotype indicates.
5. Reanalysis after 12–24 months and consideration of WGS, long-read sequencing, RNA sequencing, or tissue-specific testing for mosaicism after a nondiagnostic result.
6. Parental testing, segregation, ACMG/AMP classification, and pre/post-test genetic counseling.

A 2024 first-line WES series found pathogenic variants in 35/82 (43%); 66% were de novo, and missense variants comprised 75%. A prospective early-infantile cohort achieved a molecular diagnosis in 53/77 (69%), with NGS yield 51% and microarray yield 14%. Rapid genome sequencing in infants with early seizures identified genetic etiologies in 46%, produced clinical utility in 56%, and informed prognostic counseling in 86%, with median 37 days to result. (scheffer2024developmentalandepileptic pages 9-11, chang2023genetictestingin pages 4-6)

Testing after a negative exome can still be useful because WGS detects noncoding, structural, and difficult-to-sequence variants. Single-gene testing is appropriate when a phenotype is highly specific, but broad sequencing usually performs better for heterogeneous DEE. Karyotype and FISH have limited first-line roles unless a known rearrangement is suspected.

Differential diagnoses include acquired hypoxic–ischemic injury, infection, immune encephalitis, structural epilepsy, cerebral malformation, metabolic/vitamin-responsive epilepsy, neurodegenerative disease, and developmental disability with coincidental epilepsy. There is no general newborn-screening program for DEE, although individual metabolic causes may be included in national panels.

11. Outcome and prognosis

Outcome is strongly genotype-, variant-, and syndrome-dependent. Many affected people have lifelong intellectual and adaptive disability, impaired communication, dependence for daily activities, movement disorder, feeding problems, orthopedic complications, and drug-resistant epilepsy. Seizure freedom does not necessarily reverse the primary developmental encephalopathy.

In 510 people with common genetic DEEs, convulsive status epilepticus occurred in 47%, nonconvulsive status in 19%, and 42/510 (8%) died. Overall mortality was 6.1 per 1,000 person-years; 19/42 deaths were SUDEP, giving an estimated SUDEP rate of 2.8 per 1,000 person-years. CSE occurred in 89% of the Dravet subgroup and was also frequent in KCNT1- and SCN2A-related disease. SUDEP was observed in SCN1A-, SCN2A-, SCN8A-, and STXBP1-associated groups. These data support gene-specific emergency plans and SUDEP counseling. (scheffer2024developmentalandepileptic pages 19-21)

Poor prognostic factors include early and severe epilepsy, recurrent status, profound early developmental impairment, pathogenic mechanisms producing major protein dysfunction, progressive/metabolic disease, and severe feeding or respiratory comorbidity. In Dravet syndrome, poorer baseline language, greater initial epilepsy severity, and a worse SCN1A genetic score predicted poorer ten-year development. More than 90% of caregivers reported adverse effects on their health and career opportunities. (scheffer2024developmentalandepileptic pages 17-19)

No valid umbrella five- or ten-year survival percentage exists. Prognosis should be communicated by gene, variant mechanism, syndrome, and individual trajectory.

12. Treatment

Standard multimodal care

Treatment includes syndrome-appropriate antiseizure medication, emergency rescue medication and status plan, dietary therapy, and—when indicated—epilepsy surgery, vagus-nerve stimulation, or other neuromodulation. Developmental, physical, occupational, speech/augmentative-communication, feeding, sleep, behavioral, orthopedic, visual, and psychosocial care are essential.

Suggested MAXO mappings include antiseizure pharmacotherapy, electroencephalography, brain MRI, molecular genetic testing, ketogenic diet therapy, vagus-nerve stimulation, epilepsy surgery, physical therapy, occupational therapy, speech therapy, gastrostomy, genetic counseling, and seizure-emergency planning. Exact MAXO identifiers should be resolved against the current ontology release.

Genotype- and syndrome-directed examples

• SCN1A loss-of-function Dravet syndrome: valproate, clobazam, stiripentol, cannabidiol, and fenfluramine are commonly used according to jurisdiction and patient profile. Sustained sodium-channel blockers can aggravate seizures in many patients and are generally avoided, although emergency-use decisions remain clinical.
• KCNQ2/SCN2A/SCN8A channelopathy: sodium-channel blockers may be beneficial in selected gain-of-function phenotypes but harmful in others; functional direction and age-dependent phenotype matter.
• TSC1/TSC2 with infantile spasms: vigabatrin is an important syndrome-specific treatment; mTOR inhibition is relevant for selected tuberous-sclerosis manifestations.
• SLC2A1 deficiency: ketogenic diet directly supplies alternative cerebral fuel.
• Pyridoxine/PLP/folinic acid/biotin-responsive disorders: prompt vitamin/cofactor therapy can be transformative.
• Focal structural/mTOR-pathway disease: resective or ablative surgery can be considered when a localized epileptogenic lesion is demonstrated.

Genetic diagnosis prompted medication changes in nearly half of patients in some reviewed series, but precision benefit is uneven and many interventions remain based on small cohorts or mechanistic inference. (specchio2024theexpandingfield pages 6-8)

Emerging therapies and trials

• ETX101, SCN1A-positive Dravet syndrome: AAV9 delivers a GABAergic regulatory element and engineered transcription factor to increase endogenous SCN1A transcription. WAYFINDER, NCT06112275, is Phase 1/2, active but not recruiting, with 4 children enrolled; EXPEDITION, NCT06283212, is Phase 1/2, active but not recruiting, with 5 children. Primary outcomes include safety, monthly seizure-frequency change, prolonged seizures/status, and development. These are early safety/efficacy studies, not evidence of established benefit. URLs: https://clinicaltrials.gov/study/NCT06112275 and https://clinicaltrials.gov/study/NCT06283212. (NCT06112275 chunk 1, NCT06283212 chunk 1)
• STXBP1 gene therapy: CAP-002, NCT06983158, entered Phase 1/2 pediatric evaluation but the retrieved record reports termination after enrollment of one participant; no efficacy conclusion is possible. URL: https://clinicaltrials.gov/study/NCT06983158. (NCT06983158 chunk 2)
• Ataluren for nonsense variants: NCT02758626 was a completed Phase 2 randomized crossover trial in CDKL5 or Dravet cases with nonsense mutations, enrolling 15 children. It tested premature-stop-codon read-through; the record alone does not establish efficacy. URL: https://clinicaltrials.gov/study/NCT02758626. (NCT02758626 chunk 1, NCT02758626 chunk 2)
• CDKL5 hyperthermic baths: NCT06447675 was an eight-person feasibility study of 20-minute daily 40–42°C baths; a 34-person PROBE trial, NCT07602205, is planned. This unconventional intervention lacks established efficacy and should only be considered in a research protocol with safety oversight. URLs: https://clinicaltrials.gov/study/NCT06447675 and https://clinicaltrials.gov/study/NCT07602205. (NCT06447675 chunk 1, NCT07602205 chunk 1)
• RNA therapeutics: antisense oligonucleotides have improved phenotypes in preclinical SCN1A, SCN2A, SCN8A, and KCNT1 models. TANGO-type approaches increase productive gene output. Human efficacy and long-term neurodevelopmental effects remain unproven. (scheffer2024developmentalandepileptic pages 17-19)

No curative therapy is currently established for genetic DEE as a group. Authoritative reviews emphasize that trial endpoints should include development, behavior, sleep, motor function, and caregiver burden in addition to seizures. (specchio2024theexpandingfield pages 1-6, specchio2024theexpandingfield pages 17-21)

13. Prevention

Primary prevention by lifestyle modification or vaccination is not applicable to a spontaneous pathogenic variant. Relevant preventive strategies are:

• Reproductive prevention/options: genetic counseling, parental segregation and mosaicism testing, carrier testing for recessive/X-linked disease, prenatal diagnosis, and preimplantation genetic testing when the familial variant is known.
• Secondary prevention: rapid genetic/metabolic diagnosis, early syndrome-specific treatment, developmental intervention, and cascade testing where relatives may carry a pathogenic variant.
• Tertiary prevention: individualized status plans, rescue medication, medication adherence, trigger management, drowning and bathing precautions, sleep and respiratory management, feeding/aspiration care, bone health, and explicit SUDEP counseling.

Population newborn genomic screening for DEE is not standard. Some treatable metabolic causes are detected by conventional newborn screening, depending on jurisdiction.

14. Other species and natural disease

DEE is not a transmissible disease and has no zoonotic potential. Homologous epilepsy/neurodevelopmental phenotypes can occur naturally in veterinary species, but “genetic DEE” is not a single cross-species veterinary diagnosis. Gene- and breed-specific entries should be sought in OMIA and the Vertebrate Breed Ontology rather than inferred from the human umbrella.

Orthologues of major genes—including SCN1A, SCN2A, KCNQ2, STXBP1, CDKL5, CHD2, and SYNGAP1—are evolutionarily conserved across mammals and many vertebrates, enabling comparative study of channel, synaptic, and developmental mechanisms. NCBI Taxonomy identifiers commonly used in research include human 9606, mouse 10090, zebrafish 7955, fruit fly 7227, and C. elegans 6239.

15. Model organisms and experimental systems

Models include knock-out, knock-in, haploinsufficient, conditional, and humanized mice; zebrafish, Drosophila, Xenopus, and C. elegans; heterologous electrophysiology systems; patient-derived iPSC neurons; CRISPR-isogenic lines; and cerebral organoids.

Applications: variant functional classification, developmental timing, cell-type-specific excitability, seizure-network analysis, transcriptomic/proteomic profiling, drug screening, viral-vector biodistribution, and gene/RNA-therapy proof of concept.

In SCN1A mouse models, viral delivery or transcriptional activation directed toward relevant brain regions or GABAergic neurons reduced hyperthermia-induced seizures; CAV-2 delivery to thalamus and hippocampus improved survival and spontaneous seizures. These are preclinical results and do not establish human safety or efficacy. (specchio2024theexpandingfield pages 14-17)

Patient-derived iPSC neurons preserve the human genetic background and can be paired with CRISPR-corrected controls; organoids permit study of early cortical development and cell-type interactions. Limitations include immature cellular states, variable differentiation, incomplete vascular/immune architecture, and poor modeling of long-range circuits and whole-organism pharmacology.

Animal-model limitations are equally important. Species differences in channel expression, brain development, and genetic background can alter seizure phenotypes. For example, some CHD2 mouse models do not develop seizures despite the human disorder, prompting use of zebrafish, frogs, patient-derived cells, and cortical organoids. (sun2024strategiesfordissecting pages 14-15)

Current expert assessment and priority gaps

The strongest expert consensus is that DEE care should move from electroclinical labels alone toward integrated electroclinical–genomic diagnosis, while retaining syndrome labels where they guide treatment and prognosis. Mechanism must be established at the variant level: the same gene family can contain both gain- and loss-of-function disease, making indiscriminate “gene-based” treatment unsafe. (specchio2024theexpandingfield pages 6-8)

Major gaps are unresolved genetic diagnoses; limited ancestry diversity; uncertain VUS interpretation; scarce longitudinal adult data; weak developmental biomarkers; inadequate natural-history controls; undermeasurement of sleep, movement, communication, and caregiver outcomes; and uncertain durability, immunogenicity, and developmental timing of gene/RNA therapies. International registries, functional assays, multi-omics, and prospective studies beginning before treatment are therefore priorities. (specchio2024theexpandingfield pages 1-6, specchio2024theexpandingfield pages 17-21)

Key recent sources

1. Scheffer IE et al. Developmental and epileptic encephalopathies. Nature Reviews Disease Primers. Published September 2024;10:61. DOI/URL: https://doi.org/10.1038/s41572-024-00546-6. Authoritative disease primer. (scheffer2024developmentalandepileptic pages 9-11, scheffer2024developmentalandepileptic pages 1-4)
2. Specchio N et al. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. Lancet Child & Adolescent Health. Published November 2024;8:821–834. DOI/URL: https://doi.org/10.1016/S2352-4642(24)00196-2. Expert review of mechanisms and emerging therapies. (specchio2024theexpandingfield pages 1-6, specchio2024theexpandingfield pages 17-21)
3. Chang Y-T et al. Genetic Testing in Children with Developmental and Epileptic Encephalopathies. Children. Published March 2023;10:556. DOI/URL: https://doi.org/10.3390/children10030556. (chang2023genetictestingin pages 4-6)
4. Cavirani B et al. Genetic Epilepsies and Developmental Epileptic Encephalopathies with Early Onset: A Multicenter Study. International Journal of Molecular Sciences. Published January 2024;25:1248. DOI/URL: https://doi.org/10.3390/ijms25021248. (cavirani2024geneticepilepsiesand pages 2-4, cavirani2024geneticepilepsiesand pages 4-6)
5. Donnan AM et al. Rates of Status Epilepticus and Sudden Unexplained Death in Epilepsy in People With Genetic DEEs. Neurology. Published April 2023;100:e1712–e1722. DOI/URL: https://doi.org/10.1212/WNL.0000000000207080. (scheffer2024developmentalandepileptic pages 19-21)

Representative exact abstract wording

Recent abstracts describe DEEs as “severe neurodevelopmental disorders characterized by recurrent, usually early-onset, epileptic seizures accompanied by developmental impairment” and emphasize that impairment is “often related to both underlying genetic etiology and abnormal epileptiform activity.” A 2024 longitudinal Dravet abstract concluded that the “negative impact of epilepsy severity at baseline on long-term developmental outcomes highlights the importance of implementing early and focused therapies.” These quotations support the dual-causation model and early-intervention rationale, but do not imply that seizure suppression alone normalizes development. (scheffer2024developmentalandepileptic pages 1-4, scheffer2024developmentalandepileptic pages 17-19)

PMID note: DOI URLs are supplied for reliable record resolution. PMIDs should be imported directly from PubMed during database ingestion rather than inferred where they were not explicitly present in the retrieved source metadata.

References

1. (scheffer2024developmentalandepileptic pages 1-4): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

2. (chang2023genetictestingin pages 4-6): Yu-Tzu Chang, Syuan-Yu Hong, Wei-De Lin, Chien-Heng Lin, Sheng-Shing Lin, Fuu-Jen Tsai, and I-Ching Chou. Genetic testing in children with developmental and epileptic encephalopathies: a review of advances in epilepsy genomics. Children, 10:556, Mar 2023. URL: https://doi.org/10.3390/children10030556, doi:10.3390/children10030556. This article has 31 citations.

3. (specchio2024theexpandingfield pages 1-6): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

4. (scheffer2024developmentalandepileptic pages 9-11): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

5. (scheffer2024developmentalandepileptic pages 19-21): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

6. (cavirani2024geneticepilepsiesand pages 2-4): Benedetta Cavirani, Carlotta Spagnoli, Stefano Giuseppe Caraffi, Anna Cavalli, Carlo Alberto Cesaroni, Gianni Cutillo, Valentina De Giorgis, Daniele Frattini, Giulia Bruna Marchetti, Silvia Masnada, Angela Peron, Susanna Rizzi, Costanza Varesio, Luigina Spaccini, Aglaia Vignoli, Maria Paola Canevini, Pierangelo Veggiotti, Livia Garavelli, and Carlo Fusco. Genetic epilepsies and developmental epileptic encephalopathies with early onset: a multicenter study. International Journal of Molecular Sciences, 25:1248, Jan 2024. URL: https://doi.org/10.3390/ijms25021248, doi:10.3390/ijms25021248. This article has 24 citations.

7. (cavirani2024geneticepilepsiesand pages 4-6): Benedetta Cavirani, Carlotta Spagnoli, Stefano Giuseppe Caraffi, Anna Cavalli, Carlo Alberto Cesaroni, Gianni Cutillo, Valentina De Giorgis, Daniele Frattini, Giulia Bruna Marchetti, Silvia Masnada, Angela Peron, Susanna Rizzi, Costanza Varesio, Luigina Spaccini, Aglaia Vignoli, Maria Paola Canevini, Pierangelo Veggiotti, Livia Garavelli, and Carlo Fusco. Genetic epilepsies and developmental epileptic encephalopathies with early onset: a multicenter study. International Journal of Molecular Sciences, 25:1248, Jan 2024. URL: https://doi.org/10.3390/ijms25021248, doi:10.3390/ijms25021248. This article has 24 citations.

8. (specchio2024theexpandingfield pages 14-17): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

9. (sun2024strategiesfordissecting pages 14-15): Jiawan Sun, Serena Noss, Deepro Banerjee, Maitreya Das, and Santhosh Girirajan. Strategies for dissecting the complexity of neurodevelopmental disorders. Trends in Genetics, 40:187-202, Feb 2024. URL: https://doi.org/10.1016/j.tig.2023.10.009, doi:10.1016/j.tig.2023.10.009. This article has 11 citations and is from a domain leading peer-reviewed journal.

10. (scheffer2024developmentalandepileptic pages 17-19): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

11. (specchio2024theexpandingfield pages 6-8): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

12. (NCT06112275 chunk 1): A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only). Encoded Therapeutics. 2024. ClinicalTrials.gov Identifier: NCT06112275

13. (NCT06283212 chunk 1): A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome. Encoded Therapeutics. 2024. ClinicalTrials.gov Identifier: NCT06283212

14. (NCT06983158 chunk 2): A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy. Capsida Biotherapeutics, Inc.. 2025. ClinicalTrials.gov Identifier: NCT06983158

15. (specchio2024theexpandingfield pages 17-21): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

16. (NCT02758626 chunk 1): Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome. NYU Langone Health. 2016. ClinicalTrials.gov Identifier: NCT02758626

17. (NCT02758626 chunk 2): Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome. NYU Langone Health. 2016. ClinicalTrials.gov Identifier: NCT02758626

18. (NCT06447675 chunk 1): Liankun_Ren. Efficacy and Safety Evaluation of Hyperthermic Baths in the Treatment of Seizures in CDKL5 Deficiency Disorder. Xuanwu Hospital, Beijing. 2024. ClinicalTrials.gov Identifier: NCT06447675

19. (NCT07602205 chunk 1): Liankun_Ren. Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A PROBE Clinical Trial. Xuanwu Hospital, Beijing. 2026. ClinicalTrials.gov Identifier: NCT07602205

Artifacts

• Edison artifact artifact-00